Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Randomized Controlled Trial
. 2010 Apr;33(4):826-32.
doi: 10.2337/dc09-1349. Epub 2010 Jan 12.

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Peter A Gottlieb  1 , Scott Quinlan, Heidi Krause-Steinrauf, Carla J Greenbaum, Darrell M Wilson, Henry Rodriguez, Desmond A Schatz, Antoinette M Moran, John M Lachin, Jay S Skyler; Type 1 Diabetes TrialNet MMF/DZB Study Group
Affiliations
Randomized Controlled Trial

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Peter A Gottlieb et al. Diabetes Care. 2010 Apr.

Abstract

Objective: This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes. VSports手机版.

Research design and methods: A multi-center, randomized, placebo-controlled, double-masked trial was initiated by Type 1 Diabetes TrialNet at 13 sites in North America and Europe. Subjects diagnosed with type 1 diabetes and with sufficient C-peptide within 3 months of diagnosis were randomized to either MMF alone, MMF plus DZB, or placebo, and then followed for 2 years V体育安卓版. The primary outcome was the geometric mean area under the curve (AUC) C-peptide from the 2-h mixed meal tolerance test. .

Results: One hundred and twenty-six subjects were randomized and treated during the trial. The geometric mean C-peptide AUC at 2 years was unaffected by MMF alone or MMF plus DZB versus placebo. Adverse events were more frequent in the active therapy groups relative to the control group, but not significantly. V体育ios版.

Conclusions: Neither MMF alone nor MMF in combination with DZB had an effect on the loss of C-peptide in subjects with new-onset type 1 diabetes. Higher doses or more targeted immunotherapies may be needed to affect the autoimmune process VSports最新版本. .

PubMed Disclaimer

"VSports" Figures

Figure 1
Figure 1
Effect of MMF and MMF plus DZB on C-peptide over 2 years. A) The geometric means and 95% CIs for the 2-h AUC stimulated C-peptide levels over time within each group. B) The cumulative incidence of decline in peak C-peptide to <0.2 pmol/ml within each group. The relative hazard was 0.61 (95% CI: 0.28–1.33, P = 0.11) for MMF plus DZB vs. control, and 1.05 (0.50–2.19, P = 0.83) for MMF alone vs. control. C) Ratio of geometric means for MMF plus DZB vs. control groups, with 95% CIs, within subgroups of subjects defined at baseline. D) Likewise for MMF alone vs. control (A1C 2nd tertile upper 95% confidence limit is 28.9).
Figure 2
Figure 2
Effect of MMF and MMF plus DZB on glycemic control over time. A) Mean A1C (%) and 95% confidence limits over time. B) Mean insulin dose and 95% confidence limits over time within each group.
See this image and copyright information in PMC

Comment in

References

    1. Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 2005;12:481–490 - PubMed
    1. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692–1698 - PubMed
    1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598–2608 - PubMed
    1. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166–173 - PMC - PubMed
    1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - "VSports app下载" PubMed

Publication types (V体育ios版)

MeSH terms